Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery

AI Insight

This case report describes the development of a neuroepithelial tumor in a patient who had previously received adeno-associated virus (AAV) gene therapy delivered via intracisternal magna injection. Genomic analysis revealed integration of the AAV vector into the patient's genome at or near the tumor site, raising the possibility of insertional mutagenesis as a contributing mechanism to tumorigenesis. While a definitive causal relationship has not been established, the finding represents a serious adverse event warranting careful evaluation of AAV integration patterns and oncogenic risk in gene therapy applications.

Why it matters

This report raises important safety concerns for AAV-based gene therapies delivered directly to the central nervous system, potentially prompting reassessment of delivery routes, vector design, and long-term monitoring protocols in both ongoing and future clinical trials.